Insider Selling: GeneDx (NASDAQ:WGS) CEO Sells $579,619.92 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 3,639 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $159.28, for a total transaction of $579,619.92. Following the completion of the sale, the chief executive officer directly owned 6,344 shares in the company, valued at approximately $1,010,472.32. This trade represents a 36.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, October 29th, Katherine Stueland sold 2,158 shares of GeneDx stock. The shares were sold at an average price of $136.54, for a total transaction of $294,653.32.
• On Tuesday, September 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $121.47, for a total transaction of $1,275,556.47.

GeneDx Stock Down 2.5%

Shares of NASDAQ:WGS opened at $151.51 on Friday. The stock’s 50-day moving average is $139.26 and its 200 day moving average is $113.84. The company has a market cap of $4.38 billion, a PE ratio of 1,683.44 and a beta of 1.99. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. GeneDx Holdings Corp. has a 1 year low of $55.17 and a 1 year high of $170.87.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.21. GeneDx had a return on equity of 20.22% and a net margin of 0.52%.The business had revenue of $116.74 million during the quarter, compared to analysts’ expectations of $104.33 million. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Guggenheim reissued a “buy” rating and set a $170.00 price objective (up from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. Zacks Research cut shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 2nd. Wells Fargo & Company raised their price objective on shares of GeneDx from $95.00 to $140.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 4th. Canaccord Genuity Group set a $160.00 price objective on GeneDx and gave the company a “buy” rating in a research report on Wednesday, October 29th. Finally, Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $133.11.

Institutional Investors Weigh In On GeneDx

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp boosted its position in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares in the last quarter. Quarry LP raised its stake in GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after buying an additional 209 shares during the last quarter. US Bancorp DE boosted its holdings in GeneDx by 3,223.5% in the first quarter. US Bancorp DE now owns 565 shares of the company’s stock worth $50,000 after acquiring an additional 548 shares in the last quarter. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of GeneDx in the third quarter worth $65,000. Finally, AlphaQuest LLC increased its holdings in shares of GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock valued at $70,000 after acquiring an additional 594 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.